We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+33.56%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.42B
AUM Growth
+$877M
(+19%)
Cap. Flow
-$870M
Cap. Flow
% of AUM
-16.07%
Top 10 Holdings %
Top 10 Hldgs %
57.84%
Holding
236
New
154
Increased
21
Reduced
12
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oscar Health
OSCR
|
+$77.6M |
| 2 |
Baxter International
BAX
|
+$48.1M |
| 3 |
Revolution Medicines
RVMD
|
+$32.2M |
| 4 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$26.2M |
| 5 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$22.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$38.5M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$36M |
| 3 |
ACH
Accendra Health
ACH
|
+$21.8M |
| 4 |
MRUS
Merus
MRUS
|
+$20M |
| 5 |
Roivant Sciences
ROIV
|
+$18.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 78.17% |
| 2 | Technology | 0.1% |
| 3 | Industrials | 0.09% |
| 4 | Consumer Discretionary | 0.08% |
| 5 | Consumer Staples | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Blue Owl Capital
OBDC
$5.42B
| $179K | ﹤0.01% |
+12,140
| New | +$173K |
|
177
OraSure Technologies
OSUR
$273M
| $177K | ﹤0.01% |
+21,639
| New | +$142K |
|
|
NOVA
178
DELISTED
Sunnova Energy
NOVA
| $172K | ﹤0.01% |
+11,271
| New | +$123K |
|
|
RNAM
179
DELISTED
Avidity Biosciences
RNAM
| $169K | ﹤0.01% |
+18,708
| New | +$125K |
|
180
Mirion Technologies
MIR
$4.12B
| $168K | ﹤0.01% |
+16,404
| New | +$138K |
|
|
SLGC
181
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $168K | ﹤0.01% |
+66,322
| New | +$154K |
|
182
Biomea Fusion
BMEA
$91.1M
| $163K | ﹤0.01% |
+11,206
| New | +$136K |
|
183
Nurix Therapeutics
NRIX
$2.43B
| $162K | ﹤0.01% |
+15,718
| New | +$108K |
|
184
Lexicon Pharmaceuticals
LXRX
$991M
| $158K | ﹤0.01% |
+103,144
| New | +$123K |
|
|
OPLN
185
Openlane
OPLN
$4.25B
| $153K | ﹤0.01% |
+10,340
| New | +$150K |
|
186
FuelCell Energy
FCEL
$1.72B
| $141K | ﹤0.01% |
+2,936
| New | +$112K |
|
187
Hims & Hers Health
HIMS
$7B
| $137K | ﹤0.01% |
+15,431
| New | +$114K |
|
188
Anavex Life Sciences
AVXL
$232M
| $136K | ﹤0.01% |
+14,654
| New | +$101K |
|
189
Voyager Therapeutics
VYGR
$187M
| $131K | ﹤0.01% |
+15,487
| New | +$112K |
|
|
ENLC
190
DELISTED
ENLINK MIDSTREAM, LLC
ENLC
| $130K | ﹤0.01% |
+10,675
| New | +$134K |
|
191
Plug Power
PLUG
$2.87B
| $125K | ﹤0.01% |
+27,848
| New | +$146K |
|
192
Weave Communications
WEAV
$529M
| $123K | ﹤0.01% |
+10,740
| New | +$95.2K |
|
|
MDRX
193
DELISTED
Veradigm Inc. Common Stock
MDRX
| $122K | ﹤0.01% |
+11,668
| New | +$143K |
|
194
Opko Health
OPK
$936M
| $121K | ﹤0.01% |
+80,348
| New | +$116K |
|
195
AngioDynamics
ANGO
$565M
| $120K | ﹤0.01% |
+15,352
| New | +$106K |
|
196
GoPro
GPRO
$119M
| $118K | ﹤0.01% |
+34,113
| New | +$108K |
|
|
OPI
197
DELISTED
Office Properties Income Trust
OPI
| $115K | ﹤0.01% |
+15,718
| New | +$83.6K |
|
198
Applied Digital
APLD
$7.54B
| $113K | ﹤0.01% |
+16,779
| New | +$90.2K |
|
|
TERN
199
DELISTED
Terns Pharmaceuticals
TERN
| $112K | ﹤0.01% |
+17,290
| New | +$91.4K |
|
|
QSIAW
200
DELISTED
Quantum-Si Inc Warrant
QSIAW
| $105K | ﹤0.01% |
333,333
| – | – |
|
Similar funds
FT
GRQ
PCM
VA
QC
IC
NW
AAF
Deerfield Management's Q4 2023 Portfolio in Review
As of Q4 2023, Deerfield Management held 236 positions worth $5.42B, up 19% from $4.54B the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Deerfield Management withdrew a net $870M in Q4 2023, closing 14 positions and reducing 12 holdings. Its most notable exit was Intercept Pharmaceuticals, Inc., an estimated $38.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 68% a quarter earlier, followed by Technology and Industrials.
Against the trend, Deerfield Management opened a new position in Oscar Health worth $103M.
- Deerfield Management's largest Q4 2023 buy was Oscar Health: 11,246,820 shares worth $103M.
- Deerfield Management added most to Revolution Medicines in Q4 2023, an estimated $32.2M increase.
- Deerfield Management's biggest Q4 2023 reduction was Neurocrine Biosciences, cutting an estimated $36M.
- Deerfield Management fully exited Intercept Pharmaceuticals, Inc. in Q4 2023, selling an estimated $38.5M.
- Deerfield Management's ten largest holdings make up 58% of its $5.42B portfolio in Q4 2023.
- Deerfield Management opened 154 new positions and closed 14 in Q4 2023.
- Deerfield Management's portfolio value rose 19% quarter-over-quarter to $5.42B.
Based on Deerfield Management's 13F filing for Q4 2023, filed 14 Feb 2024.